AV

Anand Venkat Sangalipuram

Director DIN 03352055
DIN 03352055 First appointment Jan 2011
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jan 2011
Shareholding value β€’β€’β€’β€’ Premium profile

About Anand Venkat Sangalipuram

Data last updated:

Anand Venkat Sangalipuram was a Director at Autodynamics Auto India Private Limited (from 2014) and Director at Thesis Pharmaceuticals Private Limited (from 2011).

DIN 03352055
First Appointment 03 Jan 2011
Oldest Company Age 15 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Jan 20142014₹26 Lakh (FY 2017)Strike Off
Director03 Jan 20112011Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Autodynamics Auto India Private Limited
Thesis Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Anand Venkat Sangalipuram

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anand Venkat Sangalipuram

Anand Venkat Sangalipuram was first appointed on 03 Jan 2011 as Director at Thesis Pharmaceuticals Private Limited. The most recent appointment on record is 27 Jan 2014 at Autodynamics Auto India Private Limited.

Anand Venkat Sangalipuram held 2 earlier board appointments: Autodynamics Auto India Private Limited (Director, from 27 Jan 2014); Thesis Pharmaceuticals Private Limited (Director, from 03 Jan 2011).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available